Page 1

Osobi rare strength Investing in growth January - March • Total revenue of SEK 3,661 M ( 4,639 ) , -21 per cent and -13 per cent at CER • EBITA¹ was SEK 1,484 M ( 2,173 ) , with an EBITA margin¹ of 41 per cent ( 47 ) Earnings per share ( EPS ) before dilution of SEK 2.36 ( 4.02 ) • Haematology sales were SEK 1,877 M ( 2,394 ) , Doptelet® grew by 222 per cent at CER to SEK 180 M • Sales for Elocta® was SEK 857 M ( 1,359 ) , for Alprolix® SEK 413 M ( 488 ) , with patient growth of 6 and 16 per cent • Immunology sales were SEK 1,554 M ( 1,800 ) , Gamifant® grew by 47 per cent at CER to SEK 133 M • Cash flow from operating activities of SEK 1,699 M ( 1,886 ) • Doptelet ( avatrombopag ) was approved in the EU for treatment of ITP • Kineret ( anakinra ) was approved in Russia for the treatment of CAPS ● Outlook 2021 - unchanged • Revenue for the full - year 2021 is expected to be in the range of SEK 14,000-15,000 M • EBITA margin is expected to be in the range of 30-35 per cent of revenue Financial summary 1 Amounts in SEK M Total revenue Gross profit Gross margin¹ EBITA EBITA adjusted ¹ , 2 EBITA margin¹ EBITA margin adjusted ¹ , 2 Profit for the period Earnings per share , before dilution , SEK Earnings per share , before dilution , SEK adjusted ¹ , 2,3 Q1 2021 3,661 2,935 80 % SOBI Q1 REPORT 2021 1,484 1,484 41 % 41 % 696 2.36 2.36 Q1 2020 4,639 3,598 78 % 2,173 2,173 47 % 47 % 1,182 4.02 4.02 Alternative Performance Measures ( APMs ) , see page 17 for further information . ²EBITA full - year 2020 excluding non - recurring items ; other operating income related to the reversal of the CVR liability of SEK 399 M. ³EPS full - year 2020 excluding the reversal of the CVR liability of SEK 399 M. Q1 2021 report Total revenue , SEK M 3,661 EBITA margin¹ 41 % Change -21 % -18 % -32 % -32 % -41 % -41 % -41 % Full - year 2020 15,261 12,036 79 % 6,700 6,301 44 % 41 % 3,245 11.01 9.66